Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
In-vitro MICs and minimum bactericidal concentrations (MBCs) of daptomycin, linezolid, tigecycline, vancomycin and teicoplanin against Gram-positive bacteria were determined using the broth microdilution method for ten blood isolates each of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), including two vancomycin-intermediate S. aureus (VISA), vancomycin-resistant Enterococcus faecium and Enterococcus faecalis. One strain of VISA was tested in a time-kill synergism assay of daptomycin combined with oxacillin, imipenem, rifampicin and isepamicin. Daptomycin showed excellent in-vitro bactericidal activity against all the isolates tested, with no tolerance or synergism effects when combined with other agents, except with rifampicin against VISA. Vancomycin had better bactericidal activity against MRSA and MSSA than did teicoplanin. Linezolid had the poorest bactericidal activity against the isolates tested, with 100% tolerance by the MSSA and VRE isolates, and 80% tolerance by the MRSA isolates. Tolerance towards tigecycline was exhibited by 40% of the MRSA isolates, 100% of the MSSA and vancomycin-resistant E. faecalis isolates, and 90% of the vancomycin-resistant E. faecium isolates.
Huang
Y-T
YT
Department of Internal Medicine, Far Eastern Memorial Hospital, Taipei County, Taipei, Taiwan.
Liao
C-H
CH
Teng
L-J
LJ
Hsueh
P-R
PR
D000081:Acetamides / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D017576:Daptomycin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D006020:Glycopeptides / Q000494:pharmacology; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000382:microbiology*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests / Q000379:methods; D008911:Minocycline / Q000031:analogs & derivatives / Q000494:pharmacology; D023303:Oxazolidinones / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects; D013289:Streptococcaceae / Q000187:drug effects / Q000302:isolation & purification; D013624:Taiwan; D017334:Teicoplanin / Q000494:pharmacology; D000078304:Tigecycline; D013997:Time Factors; D014640:Vancomycin / Q000494:pharmacology
D000081:Acetamides; D000890:Anti-Infective Agents; D006020:Glycopeptides; D023303:Oxazolidinones; D017334:Teicoplanin; D014640:Vancomycin; D000078304:Tigecycline; D008911:Minocycline; D000069349:Linezolid; D017576:Daptomycin